Advertisement

Topics

BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint

03:19 EDT 19 Oct 2016 | Reuters

* Merck announces pivotal phase 3 study of letermovir, an investigational antiviral medicine for prevention of cytomegalovirus (cmv) infection in high-risk bone marrow transplant patients, met primary endpoint

Original Article: BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint

NEXT ARTICLE

More From BioPortfolio on "BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint"

Quick Search
Advertisement
 

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...